Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR‐215757), a new quinoline‐3‐carboxamide derivative: Studies in lupus‐prone mice and a multicenter, randomized, double‐blind, placebo‐controlled, repeat‐dose, dose‐ranging study in patients with systemic lupus erythematosus
Anders Bengtsson(Lund University), Tomas Leanderson(Lund University), Helén Tuvesson(Active Biotech (Sweden)), Birgitta Sparre(Active Biotech (Sweden)), Lars Rönnblom(Uppsala University), Marie Öhman(Active Biotech (Sweden)), Christian Lood(University of Washington), Ronald van Vollenhoven(Amsterdam University Medical Centers), Bengt Axelsson(Active Biotech (Sweden)), Gunnar Sturfelt(Lund University)
Cited by 124
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Transancestral mapping and genetic load in systemic lupus erythematosus
|Nature Communications|2017|436
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
|Nature Immunology|2003|363